Therapeutic Response
PD-L1 >= 1% status confers therapeutic sensitivity to Cisplatin in combination with Gemcitabine and Nivolumab in patients with Non-Small Cell Lung Cancer.
Statements
| Source and description |
|---|
PD-L1 >= 1% status confers therapeutic sensitivity to Cisplatin in combination with Gemcitabine and Nivolumab in patients with Non-Small Cell Lung Cancer.
| Source and description |
|---|